📊 LIANY Key Takeaways
Is LIANY a Good Investment? Thesis Analysis
LianBio is a pre-commercial pharmaceutical company burning cash at an unsustainable rate (-$53M FCF annually) against minimal revenue ($7.9M), with only ~2 years of cash runway at current burn levels despite a strong $103.5M cash position. While revenue growth is impressive percentage-wise and the balance sheet is unlevered, the company faces severe path-to-profitability challenges with extremely negative margins (-886% net margin) and stale financial data (September 2023) obscuring current status.
Why Buy LIANY? Key Strengths
- Strong balance sheet with $103.5M cash and zero debt exposure
- Exceptional liquidity position (10.06x current and quick ratios)
- Revenue growth of 1678% YoY demonstrates early commercial traction
- Minimal debt burden and low financial leverage risk
LIANY Investment Risks to Consider
- Unsustainable cash burn of $53M annually relative to $7.9M revenue
- Extreme operating losses of $77.3M create multi-year profitability gap
- Estimated ~2 year cash runway at current burn rate
- Financial data severely outdated (September 2023, nearly 2.5 years old)
- Zero insider Form 4 activity in past 90 days suggests limited confidence
- Pre-commercial pharma stage with unproven drug pipeline viability
Key Metrics to Watch
- Operating cash flow trend and burn rate acceleration/deceleration
- Total cash balance depletion rate and months of runway remaining
- Revenue growth trajectory and gross margin development
- Capital raise activities and dilution impact
- Regulatory milestones and clinical trial advancement
LIANY Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 10.06x current ratio provides a solid financial cushion.
LIANY Profitability Ratios
LIANY vs Healthcare Sector
How LianBio compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is LIANY Overvalued or Undervalued?
Based on fundamental analysis, LianBio has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
LIANY Balance Sheet & Liquidity
LIANY 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: LianBio's revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-5.71 indicates the company is currently unprofitable.
LIANY Growth Metrics (YoY)
LIANY Capital Allocation
LIANY SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for LianBio (CIK: 0001831283)
📋 Recent SEC Filings
❓ Frequently Asked Questions about LIANY
What is the AI rating for LIANY?
LianBio (LIANY) has an AI rating of SELL with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are LIANY's key strengths?
Claude: Strong balance sheet with $103.5M cash and zero debt exposure. Exceptional liquidity position (10.06x current and quick ratios).
What are the risks of investing in LIANY?
Claude: Unsustainable cash burn of $53M annually relative to $7.9M revenue. Extreme operating losses of $77.3M create multi-year profitability gap.
What is LIANY's revenue and growth?
LianBio reported revenue of $7.9M.
Does LIANY pay dividends?
LianBio does not currently pay dividends.
Where can I find LIANY SEC filings?
Official SEC filings for LianBio (CIK: 0001831283) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is LIANY's EPS?
LianBio has a diluted EPS of $-0.65.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is LIANY a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, LianBio has a SELL rating with 72% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is LIANY stock overvalued or undervalued?
Valuation metrics for LIANY: ROE of -34.4% (sector avg: 15%), net margin of -886.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy LIANY stock in 2026?
Our dual AI analysis gives LianBio a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is LIANY's free cash flow?
LianBio's operating cash flow is $-52.8M, with capital expenditures of $229.0K. FCF margin is -674.2%.
How does LIANY compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -886.0% (avg: 12%), ROE -34.4% (avg: 15%), current ratio 10.06 (avg: 2).